Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Revolution Medicines, Inc.

RVMD ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$190.27

▲ +0.82%

Market Cap $40.78B · Vol 326.80K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$40.78B

Large Cap

Div Yield

N/A

EPS Growth

-61.13%

YoY

RSI (14)

50.38

Momentum

Beta

1.43

vs Market

52W High

$224.24

15.84% below

52W Low

$56.66

233.07% above

Volume

326.80K

Avg 643.51K

P/B

9.62

Price-to-book

ROE

-58.07%

Return on equity

Free Float

97.58%

Public shares

Shariah Compliance8 STANDARDS

✗ Revolution Medicines, Inc. (RVMD) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RVMD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.37%

-6.95%

+5.17%

+35.38%

YTD

+138.88%

+227.94%

+922.41%

+546.52%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-1,131,301,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-58.07%
ROA · ROIC	-46.06% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	9.62
P/FCF	N/A
EPS Growth	-61.13%
Outstanding Shares	214.34M

Technical Indicators

50-Day SMA	$199.63
200-Day SMA	$155.69
RSI (14)	50.38
Beta	1.43
52-Week High	$224.24
52-Week Low	$56.66

Volume Today	326.80K
Avg Daily Volume (30D)	643.51K
Relative Volume	0.51x
Volatility (10D)	55.08
Volatility (30D)	45.61
Free Float	97.58%

Analyst Consensus

BUY

Current Price $190.27

Mean Target $256.76

52W Low$56.66 52W High$224.24

Current

Target

$56.66 $224.24

Current Analyst target

+34.94% upside potential · 25 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00829F4Q7

ISINUS76155X1000

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.75% ONC BeOne Medicines AG -0.48% 068270.KS Celltrion, Inc. -0.26% MEDP Medpace Holdings, Inc. -2.18% CRL Charles River Laboratories International, Inc. +0.57%

Company Profile

Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.